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With the Food and Drug Administration (FDA) approval of nusinersen (tradename Spinraza) for
treatment of spinal muscular atrophy patients on December 23 [1], 2016 brought us not one, but
two approved splice modulating oligonucleotides to treat neuromuscular disorders. Eteplirsen, an
oligonucleotide to treat a subset of Duchenne muscular dystrophy (DMD) patients, was approved
earlier this year. However, where the approval of eteplirsen was highly controversial [2], this one
seemed to be crystal clear: the drug was approved only 91 days after Bioeen filed the new drug
application (NDA) with FDA, and the application was not referred to an FDA advisory committee
because "outside expertise was not necessary and there were no controversial issues that would
have benefited from advisory committee discussion" [3].
Spinal muscular atrophy is an autosomal recessively inherited disease, that is characterized by
progressive loss of motorneurons, leading to muscle atrophy and paralysation. Most patients (60%)
suffer from the most severe form of the disease, type I SMA. Symptoms start in infants before 6
months of age, patients never achieve independent sitting, need intensive supportive care, including
ventilation, and seldom live beyond two years of age. Type II and type III SMA are milder forms of
the disease. For type II onset is after 6-18 months, patients are able to sit independently but never
able to walk and can live 20-40 years with good supportive care. Type III SMA patients are able to
walk, but generally loose this ability when disease progresses. Survival is normal. It should be noted
that all types of SMA are severe and debilitating and that the term "milder" is only relative to the
very severe type I SMA. There is a type IV SMA, with onset in adulthood (after 30 years of age) and a
slowly progressive course, but this is a very rare form [4].
Type I-IV SMA are all caused by loss of function mutations involving the SMN1 gene, precluding the
production of the protein survival of motor neurons (SMN). As the name suggests, this protein is
crucial for the survival of motorneurons. SMN is ubiquitously expressed and is a component of the
SMN complex, which has a role in assembling the small nuclear RNA proteins (snRNPs) involved in
the splicing process [5]. It is not yet fully elucidated why lack of SMN protein primarily appears to
have an impact on motorneurons.
Complete lack of SMN protein is embryonic lethal. However, humans have an almost identical copy
of the SMN1 gene, SMN2. Transcripts of this gene are unfortunately mostly improperly spliced
because exon 7 of SMN2 is poorly recognized by the spliceosome due to single nucleotide changes.
As such exon 7 is spliced out in 90% of SMN2 transcripts, leading to only ~10% offull-length SMN2
transcripts and low levels of SMN protein, which are sufficient to prevent lethality before birth, but
not enough to prevent the loss of motorneurons in infancy (type I) or childhood (type II and III) [4,5].
The reason that some patients suffer from a more severe disease than others, is that there is copy
number variation of the SMN2 gene. Type I patients generally have 2 SMN2 copies, while type II and
type III patients generally have 3 and 3-4 copies, respectively [4]. While for each SMN2 transcript
only 10% contains exon 7, the absolute amount offull-length transcripts —and thus SMN protein - of
course increases when patients have more gene copies, leading to a less severe disease.
Since all SMA patients have at least two copies of the SMN2 gene, and since more SMN protein is
associated with a less severe disease, it stands to reason that increasing the amount offull-length
SMN2 transcripts would be therapeutic. This is where nusinersen comes into play. The 2'-O-
methoxyethyl phosphorothioate antisense oligonucleotide targets a region in intron 7 that harbours
an intronic splicing inhibitor, which is one of the main reasons why exon 7 is skipped in SMN2
transcripts [6]. Blocking this site prevents splicing inhibitory factors from binding and leads to better
recognition of exon 7 by the splicing machinery and therefore more inclusion into SMN2 mRNA,
allowing increased translation of SMN protein. This approach has been proposed first by Adrian
Krainer's group, who have performed preclinical tests in cell and animal models in collaboration with
lonis Pharmaceutics. In severe animal models nusinersen treatment resulted in increased levels of
SMN protein on a molecular level, and increased survival and improved function [7].
The clinical development was coordinated by lonis Pharmaceuticals, with support from Biogen. Since
antisense oligonucleotides do not cross the blood brain barrier, intrathecal delivery was required to
target the motorneurons. The feasibility of this approach was tested in a Phase I trial in type II and
type III SMA patients (2-14 years old) [8]. This revealed that the procedure was well tolerated.
Furthermore, an increase in function as measured by the Hammersmith Motor Function Scale
Expanded was observed for patients treated with the highest dose (9 mg), leading to cautious
optimism. Several trials were then initiated for type I and type II/III SMA [9, 10, 11]. An open label
study in type I SMA showed significant divergence from natural history for survival and age of
permanent ventilation, and incremental achievements of motor milestones and increases in motor
function as measured with the Children's Hospital of Philadelphia Infant Test of Neuromuscular
Disorders (CHOP-INTEND) scale [9]. Interim analysis of aplacebo-controlled trial for type I patients
revealed a significant improvement in the achievement of motor milestones for nusinersen treated
patients compared to sham-treated patients, thus meeting the pre-specified primary endpoint for
interim analysis [10]. Furthermore, the interim analysis of aplacebo-controlled trial in type II SMA
patients revealed that nusinersen treated patients had a significantly higher increase in motor
function than placebo-treated patients, thus also meeting the pre-specified primary endpoint [11].
Both trials revealed a good safety profile and were stopped after interim analysis, enrolling all
patients into open label trials pending regulatory approval, and an expanded open access
programme was initiated for type I SMA [10,11].
The anecdotal evidence of the very good responders presented at scientific conferences and
highlighted in social media has truly surprised everyone. This includes type I SMA patients learning
to walk and ride bicycles at an age they would normally have died or be on permanent ventilation,
and wheelchair-dependent type II and type III patients regaining the ability to walk. Biogen and lonis
filed their NDA on September 23 2016 with the FDA and shortly after with the European Medicines
Agency (EMA) as well [12]. FDA approved the drug just before Christmas on December 23, while
EMA evaluation is pending. Biogen will be in charge of commercializing nusinersenand conducting
future trials.
With 2016 bringing us two approved splice modulating antisense oligonucleotides (nusinersen and
eteplirsen, a phosphorodiamidate morpholino oligomer for DMD) as well as one that was deemed
not ready for approval by FDA (drisapersen, a 2-O-methyl phosphorothioate oligonucleotide fnr
DMD) [2], one cannot but look back and compare. The preclinical development of these three
antisense oligonucleotides was done in parallel. It was long thought that developing an antisense
therapy for SMA would be more challenging than DMD, because for DMD the target tissue (skeletal
muscle) can be reached by systemic treatment, while for SMA it cannot, because antisense
oligonucleotides do not cross the blood-brain-barrier. Thus, repeated intrathecal delivery is
required, thought to be very invasive and challenging, especially in young and fragile infants.
It has become clear, however, that targeting the central nervous system is actually easier than
targeting skeletal muscle. Upon intrathecal delivery, neurons take up antisense oligonucleotides
efficiently and oligonucleotides with a phosphorothioate backbone distribute throughout the brain
and the spinal cord, as revealed by studies in primates and posthumous analysis of nusinersen
treated SMA patients who died [9,13]. While intrathecal delivery was at first thought to be very
invasive, the trials show that this is well tolerated. An advantage of local delivery to the central
nervous system is that it allows high, local dosing at the target tissue, with a low load for liver and
kidney. By contrast, for DMD the target tissue makes up 30-40% of the human bodyweight, and high
systemic doses are required to obtain sufficient levels of oligonucleotides in the muscle to achieve
minimal levels of exon skipping and dystrophin restoration [2]. Furthermore, the central nervous
system is a benign environment for antisense oligonucleotides,and the half-life is months rather
than days-weeks for systemic organs [8, 9,13]. As such the dosing frequency can be much lower,
with a maintenance dose required every 4 months for nusinersen compared to every week for
eteplirsen [14, 15].
Another advantage of nusinersen over eteplirsen and drisapersen is that while
eteplirsen/drisapersen apply to only a subset of DMD patients with a specific mutation (13-14% of all
patients), nurisersen applies to all SMA patients, across the different types. As such nusinersen is
anticipated to be the largest commercial success in the antisense field to date. Similarly to
eteplirsen, costs are high,: an estimated $750,000 for the first year, followed by $375,000 annually
for nusinersen, compared to $400,000-$500,000 annually per patient for eteplirsen. While for
eteplirsen several health insurance companies have indicated not to reimburse the drug, or to only
reimburse for ambulant patients [2], no such statements have as yet been made for nusinersen.
However, eteplirsen received accelerated approval, based on minor increases in dystrophin levels in
a very small number of patients, with the FDA clearly stating that functional effects will need to be
shown in additional, confirmatory trials [2]. Nusinersen, by contrast, received full approval based on
clinical evaluation in 173 patients, with confirmed therapeutic effects [14]. Furthermore, eteplirsen
aims to slow down disease progression in DMD patients, while nusinersen has been shown to
improve motor function for type II/III SMA patients and to have a lifesaving effect in type I patients.
So far nusinersen is only approved in the USA. EMA evaluation is pending and expected to take place
in 2017. It is as yet unknown whether the drug will be approved in Europe (though this seems likely)
and if so, whether the EMA indication will be for all SMA types or only for type I SMA. There are
more outstanding questions: it is not yet known what the long term effects of intrathecal antisense
oligonucleotide treatrnentwill be. Given the certainty of the severe, debilitating nature of SMA
without treatment, this is an uncertainty that patients and parents find acceptable. However, post
marketing studies will need to be done to investigate both the positive and potentially negative
effects after years and decades of treatment. Another outstanding issue is the fact that SMN is
expressed ubiquitously and that local treatment results in increased levels of SMN protein only in
the neurons. In mouse models, full recovery or the life span was only observed when SMN protein
was restored both in the central nervous system and systemically [16]. It is as yet unknown whether
this finding translates also to humans, or whether it is an artifact of the model, which carries human
SMN2 genes in the absence of mouse Smn (mice only possess only one Smn gene). Again, time will
tell whether upon restoration of the deficit in neurons, systemic symptoms will become more
apparent later in life.
An ethical issue that parents and clinicians have to deal with now, is when to treat and when not to
treat. For older type I SMA patients, who are already on permanent ventilation, treatment may
prolong survival, but it is currently unknown how much improvement in muscle function will occur.
This is a very difficult and emotional decision to make by those involved, but one that hopefully will
not exist in the future if SMA patients are treated from an early age.
Finally, more drugs are in development for SMA, with the gene therapy approach from Avexis for
type I SMA having received breakthrough designation by FDA. This approach involves an adeno-
associated viral vector 9 containing the SMN1 cDNA (AVXS-101), and is being evaluated in an open
label phase 1 trial in 15 type I SMA infants. Patients have received a single intravenous dose of AVXX-
101, at a low (n=3) or high (n=12) dose. For the higher dose group, results are encouraging, with
8/12 patients achieving the ability to sit independently and 2/10 patients able to walk
independently. The advantage of this approach is that in theory it requires a single, intravenous
treatment. However, thus far the approach has only been tested in a very small group of patients
and it is not yet known how long the beneficial effects will persist. It is also unclear whether the
current trial results will be sufficient for drug approval. At the same time, obtaining more
information in clinical trials will be challenging for Avexis, and also other companies working in the
SMA field. Now that nusinersen is approved, it is unethical to perform placebo-controlled trials. Even
doing head to head comparisons between nusinersen and investigational drugs is questionable,
because it is highly unlikely that parents would willingly participate in a trial, and accept the
possibility that their child will receive an investigational drug with unconfirmed therapeutic potency,
rather than nusinersen. As such, an add-on approach would probably be most realistic, where both
arms receive nusinersen and one arm also receives the trial drug. This has of course practical
implications if both drugs have the same mechanism of action. However, for a disease as fatal and
debilitating as SMA, the fact that it is difficult to study new drugs because the current drug appears
to be working well, is of course a good problem to have.
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